![Sample our Physical Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110819/TOC-Subject-Sample-2021-Physical-Sciences.jpg"})
Abstract
Imatinib mesylate is currently the drug of choice for treatment of chronic myeloid leukaemia. There is great possibility of coadministration of this drug with antimalaria agents in malaria-endemic regions of the world. The need, therefore, arises to develop a sensitive, simple, and reliable HPLC method that could determine imatinib in human plasma in the presence of these common antimalaria agents. After protein precipitation with acetonitrile and centrifugation, the sample was subjected to isocratic elution on an Agilent Zorbax SB-Cyano column with a mobile phase consisting of methanol-phosphate buffer (0.1 M, adjusted to pH 3 with perchloric acid) (60:40%, v/v) at a flow rate of 1 ml/min and monitored at 267 nm. The method was found to be specific in determining imatinib in plasma in the presence of amodiaquine, chloroquine, proguanil, quinine, artesunate, artemether, and lumefantrine. The standard curve for imatinib was linear over the concentration range of 10–2000 ng/mL (r > 0.999) with improved recovery in the range of 96.5–98.5%. The inter- and intra-day precisions, expressed as % coefficient of variation (% CV), were lower than 10% in all the concentration levels tested, whereas assay accuracy was in the range of 97.26–109.3%. The method was used to estimate pharmacokinetic parameters of imatinib in three imatinib-naïve patients.